Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats.
about
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic ratsSubclinical Alterations of Cardiac Mechanics Present Early in the Course of Pediatric Type 1 Diabetes Mellitus: A Prospective Blinded Speckle Tracking Stress Echocardiography Study.Diabetic cardiomyopathy: pathophysiology and clinical featuresConundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria.Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy.Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function.Advanced glycation end products in children with type 1 diabetes and early reduced diastolic heart function.Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeysAn advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophyGlycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophyRole of advanced glycation end products in cardiovascular disease.Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling.Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging.Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats.Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report.Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications.Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetesNeuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular riskAdvanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.Advanced glycation endproducts in chronic heart failure.Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.Molecular mechanisms of diabetic cardiomyopathy.Diabetic Cardiomyopathy: An Immunometabolic Perspective.Diabetic cardiomyopathy--to take a long story serious.Oxidative stress in cardiac and skeletal muscle dysfunction associated with diabetes mellitus.Mechanical properties of normal and diseased cerebrovascular system.Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy.Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies.Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways.Pathophysiological Fundamentals of Diabetic Cardiomyopathy.Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study.Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
P2860
Q28367881-9C1F5841-56AA-479A-9D61-86B446052B51Q30391941-96FB5724-22D5-4FC6-B343-BCE8A35E431FQ30457504-60F79E49-7A1A-4AC6-BBAB-F5CB83315915Q33357265-7EFA782B-416E-4B3F-8EC6-18193F973507Q33691265-66301578-BA3E-436B-8604-788E1D9EEDC2Q33711031-0BD15F98-0136-4544-898D-E0E8E239ACF2Q33730962-7BCEB6F2-EBA7-4663-9273-4C7968A5E366Q33746869-626E0A1F-443B-4991-8AB0-A21F876A9DD5Q34481838-369BCE97-98E2-4D81-8018-F3B3E6555949Q34652366-70E745DC-4CDF-461D-B48B-227C099DDD69Q35081898-02152A3A-B5DB-489D-B560-BD692754C9FAQ35546284-88D1AFB5-57AB-4D72-B9CE-B596F92CE673Q35805813-B6561B0E-A027-4A81-9ECA-9D2D7B3C3FE9Q35887541-74DB0052-F287-4626-A0F5-D934FE6705ACQ35929112-8A3CCF42-4226-4538-9A4C-2EBD414A85EBQ36193769-E321B36B-21ED-4E26-8393-75039F8AAC09Q36337283-21E74001-A684-4F16-B0C5-B473E569D26CQ36358659-CB81541B-189A-4B93-BAFD-D6F250DEF018Q36373255-1C2C3814-D80C-4848-B4EB-E3923EE5D5AEQ36567763-701371E8-F9CC-415D-BB77-F33E83CF0E40Q36736336-17E3BA4E-3B35-46AA-9DA6-A7995798B293Q36775652-522DADCC-033E-43DB-87B4-1BF570A33B55Q37006353-A00D2D4E-D75F-4493-BBE4-441AF2D73F2AQ37120232-103DB5F0-A3BA-480A-89A6-1786159CB639Q37151713-171DC0DC-8733-4AED-97C7-507031A2734BQ37157943-12CDF329-F4F9-452E-B2B0-0B7F782E62C3Q37366116-024B7041-C50E-4F23-8D66-DF6B66A8861AQ37412673-F7961F9C-AAEE-4870-A370-5CB67764A7EEQ37672583-9D27FFC4-92E5-43A7-9A19-4D10F67DDE73Q37741735-DDEC4942-5F66-4CE6-82D7-107608C8373BQ37752042-A189C461-EEE3-4612-A891-579D193A35C9Q37836408-0320DC9F-FEF4-4CC4-996D-06C2F395D02DQ38003989-B55E4DF5-FE88-4B6A-B714-E8ECEE347CE5Q38061830-C5CCDB16-670C-4B77-87B4-B8E318C4D702Q38083574-1562BD57-3CC4-4A35-A92F-A87837E2066AQ38234313-EB8F4095-0F2A-47B6-A122-AF4CF64415EFQ38620860-BE751101-02F7-492B-B7BB-4F075B197F43Q39195672-F0CF19A9-BC73-43DC-BBA4-AB8BE2D7332EQ40749360-9BD5BC0D-E5F9-4280-81CF-F0291AB6B1AFQ42115221-60DC8E0F-EDB2-4604-B01C-D84B77E27EDE
P2860
Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Aminoguanidine prevents the de ...... ced diabetes mellitus in rats.
@en
Aminoguanidine prevents the de ...... ced diabetes mellitus in rats.
@nl
type
label
Aminoguanidine prevents the de ...... ced diabetes mellitus in rats.
@en
Aminoguanidine prevents the de ...... ced diabetes mellitus in rats.
@nl
prefLabel
Aminoguanidine prevents the de ...... ced diabetes mellitus in rats.
@en
Aminoguanidine prevents the de ...... ced diabetes mellitus in rats.
@nl
P2093
P1433
P1476
Aminoguanidine prevents the de ...... ced diabetes mellitus in rats.
@en
P2093
P304
P356
10.1161/01.CIR.93.10.1905
P407
P577
1996-05-01T00:00:00Z